Your browser is no longer supported. Please, upgrade your browser.
Settings
MYL Mylan N.V. daily Stock Chart
MYL [NASD]
Mylan N.V.
IndexS&P 500 P/E563.95 EPS (ttm)0.04 Insider Own0.20% Shs Outstand528.95M Perf Week-2.06%
Market Cap11.34B Forward P/E4.71 EPS next Y4.55 Insider Trans11.35% Shs Float510.16M Perf Month15.65%
Income19.90M PEG123.48 EPS next Q1.13 Inst Own88.30% Short Float3.56% Perf Quarter20.73%
Sales11.29B P/S1.00 EPS this Y-57.40% Inst Trans0.85% Short Ratio2.47 Perf Half Y-25.12%
Book/sh23.09 P/B0.93 EPS next Y5.76% ROA0.10% Target Price26.57 Perf Year-42.82%
Cash/sh0.52 P/C41.28 EPS next 5Y4.57% ROE0.30% 52W Range16.63 - 39.59 Perf YTD-21.79%
Dividend- P/FCF6.89 EPS past 5Y-16.70% ROI3.50% 52W High-45.87% Beta1.84
Dividend %- Quick Ratio0.80 Sales past 5Y10.60% Gross Margin39.90% 52W Low28.86% ATR0.85
Employees35000 Current Ratio1.40 Sales Q/Q1.50% Oper. Margin6.10% RSI (14)60.27 Volatility4.14% 3.98%
OptionableYes Debt/Eq1.12 EPS Q/Q-550.00% Profit Margin0.30% Rel Volume0.49 Prev Close21.80
ShortableYes LT Debt/Eq1.06 EarningsOct 28 BMO Payout0.00% Avg Volume7.36M Price21.43
Recom1.90 SMA206.67% SMA5010.18% SMA200-12.15% Volume3,610,498 Change-1.70%
Jul-19-19Initiated Wolfe Research Outperform
Jun-11-19Initiated Barclays Overweight $26
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
Mar-06-18Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-25-18Reiterated Susquehanna Positive $47 → $55
Jan-04-18Reiterated Citigroup Buy $48 → $58
Jan-03-18Initiated Leerink Partners Mkt Perform $44
Sep-17-19 09:30AM  Mylan Expands Oncology Portfolio with Launch of Generic Faslodex® Injection, a Treatment for Advanced Breast Cancer PR Newswire
Sep-11-19 03:50PM  Leaner Pfizer Positioned to Boost R&D Output GuruFocus.com
Sep-06-19 11:57AM  Pfizer is a Top Drugmaker: Is it the Right Time to Buy It? Zacks
Sep-05-19 09:00AM  Pfizer Stock Is A Top Pharma Company But Should You Buy It? Investor's Business Daily
Sep-04-19 07:00AM  Mapi Pharma to Present Series of Recent Advancements for Treating Multiple Sclerosis (MS) at ECTRIMS 2019 GlobeNewswire
Sep-03-19 11:00AM  Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why Zacks
06:45AM  The 3 Worst Health Care Stocks So Far This Year Barrons.com
Aug-30-19 08:22AM  3 Big Stock Charts for Friday: Mylan, Newell and Home Depot InvestorPlace
Aug-29-19 05:06PM  U.S. FDA approves Mylan generic of Lilly lung cancer drug Alimta Reuters
04:22PM  Mylan Stock Leaps As It Prepares To Knock Off $2 Billion Lilly Drug Investor's Business Daily
09:06AM  Forget Pfizer, Add These Big Drugmakers to Your Portfolio Zacks
Aug-28-19 09:30AM  Mylan (MYL) Down 12.9% Since Last Earnings Report: Can It Rebound? Zacks
Aug-27-19 11:01AM  4 Biotech Stocks to Buy That Are on the Move InvestorPlace
Aug-26-19 01:17PM  Historic Bear Signal Spells Bad News for Mylan Stock Schaeffer's Investment Research
Aug-22-19 02:39PM  Novo Nordisk Suing Mylan Over Generic Victoza Drug InvestorPlace
03:09AM  Denmark's Novo Nordisk files lawsuit against Mylan over patent Reuters
Aug-21-19 11:04AM  Teva Launches Generic Version of Mylan's EpiPen for KIds Zacks
Aug-20-19 08:23AM  Teva to launch generic version of EpiPen for young children Reuters
05:31AM  [video]Teva's Generic EpiPen Jr Is Now Available for $300 TheStreet.com
Aug-19-19 05:15AM  The 6 Worst Health-Care Stocks So Far This Month Barrons.com
Aug-15-19 11:54AM  10 Cheap Dividend Stocks to Load Up On InvestorPlace
09:48AM  Drug Stocks Sank After 2 Members of Congress Reopened a Price-Fixing Inquiry Barrons.com
09:30AM  Company News For Aug 15, 2019 Zacks
Aug-14-19 01:56PM  Lawmakers want more answers from Mylan over drug pricing probe American City Business Journals -8.52%
01:24PM  UPDATE 1-U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis Reuters
12:57PM  U.S. FDA approves TB Alliance's treatment for drug-resistant tuberculosis Reuters
12:16PM  Generic-Drug Giants Accused of Blocking Congressional Probe Bloomberg
09:50AM  Should Value Investors Pick Mylan N.V. (MYL) Stock? Zacks
07:23AM  UPDATE 3-U.S. lawmakers push Mylan, Teva over drug pricing probe Reuters
06:28AM  U.S. lawmakers push Mylan, Teva over drug pricing probe -statement Reuters
Aug-12-19 01:57PM  Pfizer's stock sinks again, toward 14-month low to pace 'Dow's' losers MarketWatch
09:44AM  Amgen Wins Enbrel U.S. Patent Litigation Against Novartis Zacks
06:23AM  Podcast: 22 Million Cars Sold in China, and Two More Numbers to Know Barrons.com
02:26AM  No-deal Brexit could deepen Europe's shortage of medicines - experts Reuters
12:00AM  Biopharma Tie-Ups and Quebecois Weed Woes Motley Fool
Aug-09-19 03:47PM  Francisco Garcia Parames' Top 6 Buys in the 2nd Quarter GuruFocus.com
Aug-06-19 06:17PM  Wall Street Advances on Tuesday GuruFocus.com -5.94%
03:36PM  Here's What's Pushing Teva Pharmaceutical Industries Stock Even Lower Today Motley Fool
Aug-05-19 03:26PM  The Vanguard Health Care Fund Buys Pfizer, Humana GuruFocus.com
02:09PM  Investors Dont Like Mylans Deal With Pfizer Barrons.com
10:59AM  Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss Zacks
10:01AM  5 Winners and 5 Losers From Earnings Season Barrons.com
Aug-04-19 10:58AM  Barclays: 3 Reasons to Buy Mylan Post Pfizer Deal TipRanks
Aug-02-19 01:09PM  After Mylan Gets Acquired, Could Teva Be Next? GuruFocus.com
10:53AM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
09:29AM  Waiting game: Will Mylan merger change local employment? American City Business Journals
Aug-01-19 03:37PM  Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates Zacks
04:00AM  Cover story: After years of challenges, Mylan looks to chart a different course American City Business Journals
Jul-31-19 10:01AM  Wednesdays Vital Data: Pfizer, Advanced Micro Devices and Apple InvestorPlace
09:34AM  Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine Zacks
07:24AM  3 Big Stock Charts for Wednesday: Southern Co, CF Industries Holdings and National-Oilwell Varco InvestorPlace
05:39AM  Pfizer: Downgrade Double-Whammy On Mylan Deal TipRanks
05:01AM  Heres How Pfizer Stock (and Pharma) Stand to Benefit From Mylan Deal InvestorPlace
Jul-30-19 05:40PM  Big drugmakers trade Peninsula plant as part of larger deal American City Business Journals
05:16PM  Edited Transcript of MYL earnings conference call or presentation 29-Jul-19 12:30pm GMT Thomson Reuters StreetEvents
04:20PM  Dow Jones Today: Trump Trade Tweets at It Again InvestorPlace
03:20PM  ETF investment opportunities amid Pfizer's deal with Mylan Yahoo Finance Video
12:14PM  Morgan Stanley Downgrades Pfizer In Wake Of Upjohn-Mylan Merger Benzinga
10:53AM  Economic and Earnings Date Deluge Zacks
10:48AM  Mylan reaches $30 million settlement in SEC's EpiPen probe Reuters
10:34AM  Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More Zacks
10:32AM  Pfizer Stock Falls for the Second Day After Mylan Deal Barrons.com
10:15AM  Pfizer's stock tumbles toward worst 2-day stretch in 10 1/2-years MarketWatch
10:06AM  Stock Market News For Jul 30, 2019 Zacks
09:49AM  Company News For Jul 30, 2019 Zacks
09:25AM  RPT-GRAPHIC-Mylan stock boost follows long share struggles for company, generics industry Reuters
09:01AM  3 Big Stock Charts for Tuesday: Hanesbrands, Tapestry and Travelers Companies InvestorPlace
07:56AM  Challenges remain for Mylan despite merger with Upjohn American City Business Journals
06:00AM  3 Key Things to Know About How the Mylan-Upjohn Merger Affects Pfizer Shareholders Motley Fool
02:09AM  Mylan deal puts future of its beleaguered EpiPen in spotlight Reuters
Jul-29-19 08:01PM  SHAREHOLDER ALERT: WeissLaw LLP Investigates Mylan N.V. PR Newswire +12.57%
06:53PM  Pfizer-Mylan Deal 'Well-Valued' for Mylan, Says Raffat Bloomberg
05:45PM  Mylan stock boost follows long share struggles for company, generics industry Reuters
05:34PM  GRAPHIC-Mylan stock boost follows long share struggles for company, generics industry Reuters
05:12PM  What Happened in the Stock Market Today Motley Fool
04:35PM  Dow Jones Today: Fed Watch Begins InvestorPlace
04:33PM  US STOCKS-U.S. stocks back off record highs ahead of Fed meeting Reuters
04:11PM  Merger Fever Runs Hot In Pharma: Viagra, Epipen Sellers Announce Matchup Investor's Business Daily
03:49PM  Dow Jones Edges Higher on Monday GuruFocus.com
03:29PM  Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer Zacks
03:28PM  Bresch would stand to gain a lot with Mylan's change in control, according to proxy American City Business Journals
03:19PM  Why Is Pfizer Stock Down Despite the Deal With Mylan? Look at the Numbers. Barrons.com
03:13PM  Mylan's Mixed 2nd-Quarter Results Overshadowed by News of Its Upjohn Merger Motley Fool
03:05PM  Pfizer to Combine Off-Patent Drug Business With Mylan GuruFocus.com
02:45PM  Mylan Inc. -- Moody's affirms Mylan's Baa3 ratings; outlook stable Moody's
02:23PM  US STOCKS-Wall Street mixed as Amazon, Facebook weigh Reuters
01:40PM  Mylans Mastermind Clutches the Reins as Pfizer Makes Its Move Bloomberg
01:31PM  Meet the CEO-in-waiting of the Mylan-Upjohn company American City Business Journals
01:17PM  Pharmacia Corporation (Old Monsanto) -- Moody's reviews Pfizer's A1 rating for downgrade; affirms P-1 rating Moody's
01:06PM  US STOCKS-Wall Street mixed as Amazon, Facebook weigh Reuters
12:24PM  Why Mylan Stock Is Jumping Today Motley Fool
12:09PM  Wall Street is not exactly impressed with the Pfizer-Mylan deal MarketWatch
12:04PM  UPDATE 1-Pfizer in talks to transition EpiPen maker into generics spinoff -spokeswoman Reuters
11:50AM  Stock Market News: Pfizer and Mylan Make a Deal; Chipotle Looks Tasty Motley Fool
11:40AM  Pfizer (PFE) Beats on Q2 Earnings, to Merge Upjohn With Mylan Zacks
11:38AM  US STOCKS-Wall St eases from record highs as tech drags; Fed meeting eyed Reuters
11:35AM  Pfizer in talks to transition EpiPen manufacturing into generics spinoff Reuters
11:04AM  Mylan, Pfizer's Upjohn To Merge And Create New Company Benzinga
10:58AM  Mylan Reports Q2 Earnings Beat Benzinga
10:58AM  For Mylan, it's bye-bye Netherlands, but Canonsburg's future role still unclear American City Business Journals
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; TB Alliance; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HIGGINS MELINA EDirectorAug 15Buy17.6820,000353,54833,120Aug 19 07:29 PM
Vollebregt Sjoerd SDirectorAug 14Buy18.8124,000451,43942,258Aug 15 06:30 PM
Vollebregt Sjoerd SDirectorAug 13Buy19.1110,000191,10018,258Aug 15 06:30 PM
COURY ROBERT JDirectorAug 02Buy20.0649,8591,000,012947,194Aug 05 08:00 AM
MARK RICHARD ADirectorJul 31Buy20.974,00083,8744,000Aug 02 06:48 PM
COURY ROBERT JDirectorJun 24Option Exercise0.00750,00001,309,835Jun 25 08:04 PM
Gallagher Daniel Martin JrChief Legal OfficerApr 01Option Exercise0.008,515021,133Apr 03 06:00 PM
Campbell PaulSee RemarksMar 04Sale27.5011,533317,14324,137Mar 05 06:15 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002190599Mar 05 06:15 PM
Campbell PaulSee RemarksMar 03Option Exercise0.00830024,493Mar 05 06:15 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0020,1420394,503Mar 05 06:06 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 03Option Exercise0.008,218016,567Mar 05 06:09 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.005,534098,537Mar 05 06:11 PM
Malik RajivPresidentMar 03Option Exercise0.0012,3950275,388Mar 05 06:11 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.003,984016,853Mar 05 06:13 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.006,103015,541Mar 05 06:13 PM
Malik RajivPresidentMar 02Option Exercise0.0014,6450269,457Mar 05 06:11 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.006,103095,657Mar 05 06:11 PM
Gallagher Daniel Martin JrChief Legal OfficerMar 02Option Exercise0.007,811012,093Mar 05 06:09 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0022,2120384,223Mar 05 06:06 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.004,02808,258Mar 05 06:33 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.004,028045,845Mar 05 06:30 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.004,56604,566Mar 05 06:27 PM
PARRISH MARK WDirectorMar 02Option Exercise0.004,028041,423Mar 05 06:25 PM
KORMAN HARRYDirectorMar 02Option Exercise0.004,566024,816Mar 05 06:23 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.004,028013,120Mar 05 06:22 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.004,028048,645Mar 05 06:21 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.004,028013,667Mar 05 06:20 PM
Cindrich Robert JDirectorMar 02Option Exercise0.004,028023,107Mar 05 06:16 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001670437Mar 05 06:15 PM
Campbell PaulSee RemarksMar 02Option Exercise0.001,980024,540Mar 05 06:15 PM
Malik RajivPresidentFeb 19Option Exercise0.0014,5890584,940Feb 21 06:01 PM
Parks Kenneth ScottChief Financial OfficerFeb 19Option Exercise0.004,837011,550Feb 21 06:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 19Option Exercise0.0025,2870751,359Feb 21 06:00 PM
Campbell PaulSee RemarksFeb 19Option Exercise0.001,216023,157Feb 21 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 19Option Exercise0.007,9430160,520Feb 21 06:00 PM
Malik RajivPresidentFeb 17Option Exercise0.0022,0240579,185Feb 20 06:02 PM
Parks Kenneth ScottChief Financial OfficerFeb 17Option Exercise0.002,14907,733Feb 20 06:00 PM
Campbell PaulSee RemarksFeb 17Option Exercise0.00540022,207Feb 20 06:00 PM
Mauro AnthonyChief Commercial OfficerFeb 17Option Exercise0.009,0150156,699Feb 20 05:00 PM
BRESCH HEATHER MChief Executive OfficerFeb 17Option Exercise0.0037,0940742,601Feb 20 05:01 PM